Treating “Untreatable” Retinal and Optic Nerve Conditions – The Stem Cell Ophthalmology Treatment Studies – Single Course

.75 CME CREDITS – $65.00

The Stem Cell Ophthalmology Treatment Study (SCOTS) is the largest ophthalmology stem cell study registered with the National Institutes of Health – www.clinicaltrials.gov Identifier NCT 01920867. SCOTS is Institutional Review Board (IRB) approved and utilizes autologous bone marrow derived stem cells (BMSC) in the treatment of optic nerve and retinal diseases. SCOTS is an open label, non-randomized, efficacy study. There is no placebo or sham arm. All patients meeting eligibility criteria and enrolled in the study receive active treatment. Bone Marrow aspirated from the posterior Iliac Crest is separated to provide Bone Marrow Derived Stem Cells (BMSC) within the stem cell concentrate. The treatment protocols in SCOTS have been continued in the Stem Cell Ophthalmology Treatment Study II (SCOTS 2) also IRB approved and registered with NIH Identifier NCT 03011541.

*COMPLIANCE DISCLOSURE: AMMG has made every effort to have all lectures and statements made regarding Extracellular Vesicles comply with all FDA and State and Local laws. This is a science and knowledge based course, and Extracellular Vesicles is a new and potentially changing area of medicine. Currently Extracellular Vesicles can only be used in conjunction with an IRB with a FWA plus and IND/BLA, meaning FDA approval for a phase 1 clinical trial must be granted. We encourage you to frequently check for new policies, laws and rules which may apply to your practice and to strictly adhere to all laws which apply.

CME

Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians / Nurses / Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Age Management Medicine Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 8.00 AMA PRA Category 1 CreditsTM for physicians and 8.00 contact hours for nurses and 8.00 of knowledge/ -based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.


Objectives – After attending this program you should be able to:

  1. Learn and understand the evidence-based science behind the use of Exosomes as an adjunct to an Age Management Medicine practice in the areas of biomarkers, ways of treating disease and use of targeted delivery vehicles for therapeutic molecules.
  2. Learn essential scientific information for the use of Exosomes in Age Management Medicine and how to clinically apply this knowledge to individualized treatment plans to improve outcomes.
  3. Understand how Exosomes can be applied clinically to various areas such as cardiac health, cancer, retinal and optic nerve conditions and gastrointestinal diseases.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed in the program book and have disclosed they have no relevant financial relationships.

Ian White, Ph.D.
Chief Scientific Officer, IMAC Regeneration Centers, Miami, FL
Chairman of the Scientific Committee, American Academy of Stem Cell Physicians
President, BioFirma, LLC
FACULTY DISCLOSURE:
IMAC Regeneration Centers: Scientific/Medical Advisory Board Member

Kathy O’Neil Smith, M.D.
Private Internal, Integrative and Regenerative Medicine Practice, Newton, MA
FACULTY DISCLOSURE
No Relevant Financial Interest in any Products or Services to be discussed

George Shapiro, M.D.
Adjunct Assistant Professor Clinical Medicine, New York Medical College, Valhalla, NY
Founding Partner, Cenegenics, New York City
Member, AMMG Conference Planning Committee
FACULTY DISCLOSURE:
Organicell:Scientific/Meical Advisory Board Member, Organicell Stockholder, Cellularity: Scientific / Medical Advisory Board Member

Marvin Sponaugle, M.D.
Founder & President, North Pinellas Anesthesia, Oldsmar, FL
FACULTY DISCLOSURE:
No Relevant Financial Interest in any Products or Services to be discussed

Paul Thompson, M.D.
Private Practice, Fort Worth, TX
FACULTY DISCLOSURE
No Relevant Financial Interest in any Products or Services to be discussed

Daniel Sperling, M.D.
Medical Director & Chief of Interventional Uroradiology, Sperling Prostate Center, Florida & New York
Medical Director, Sperling Medical Group, Florida
Medical Director, Sperling Neurosurgery Associates, Florida
FACULTY DISCLOSURE
No Relevant Financial Interest in any Products or Services to be discussed

Jeffrey Weiss, M.D.
Staff, Department of Surgery, North Broward Medical Center, Pompano Beach, FL
Board of Directors & Staff, Park Creek Surgery Center, Coconut Creek, FL
Staff, Al Zahra Hospital, Al Barsha, Dubai, U.A.E.
FACULTY DISCLOSURE:
No Relevant Financial Interest in any Products or Services to be discussed

Edwin Lee, M.D.
Assistant Professor of Internal Medicine, University of Central Florida, College of Medicine, Orlando, FL
Founder, Institute for Hormonal Balance, Orlando, FL
Member, AMMG Conference Planning Committee
FACULTY DISCLOSURE
No Relevant Financial Interest in any Products or Services to be discussed

Rebecca Murray, APRN, FNP-BC, CDE
Endocrine Nurse Practitioner, Institute for Hormonal Balance, Orlando, FL
Medical Director, Ward-Murray HealthCare Consulting, Groton, CT
FACULTY DISCLOSURE:
No Relevant Financial Interest in any Products or Services to be discussed

Michale “Mickey” Barber, M.D.
CEO, CMO, Better Life Carolinas, Charleston, SC
FACULTY DISCLOSURE
No Relevant Financial Interest in any Products or Services to be discussed

William Kapp III, M.D., MS, FAAOS
Founder, Chairman/CEO, Longevity Bioimaging/Landmark Hospitals, Naples, FL
FACULTY DISCLOSURE:
No Relevant Financial Interest in any Products or Services to be discussed

Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Release Date: January 15, 2020
Expiration Date: December 31, 2021

Learning Objectives:

  1. Explain the evidence-based science behind the use of Exosomes as an adjunct to an Age Management Medicine practice in the areas of biomarkers, ways of treating disease and use of targeted delivery vehicles for therapeutic molecules.
  2. Learn essential scientific information for the use of Exosomes in Age Management Medicine and how to clinically apply this knowledge to individualized treatment plans to improve outcomes.
  3. Understand how Exosomes can be applied clinically to various areas such as cardiac health, cancer, retinal and optic nerve conditions and gastrointestinal diseases.

SPECIAL OFFER

This course is part of the Exosomes: The Next Generation of Biologic Medicine bundle.
Purchase the complete series and save!

COURSE MENU

ACCOUNT MENU

NEED HELP?

FACULTY

Weiss, Jeffrey N. - M.D.
  • Staff, Department of Surgery, North Broward Medical Center, Pompano Beach, FL
  • Board of Directors & Staff, Park Creek Surgery Center, Coconut Creek, FL
  • Staff, Al Zahra Hospital, Al Barsha, Dubai, U.A.E.

Jeffrey Weiss, M.D.

Jeffrey N. Weiss, M.D., is the former Chief of Retinal Surgery at the Joslin Diabetes Center in Boston, Faculty member of Harvard Medical School, and Visiting Scientist at the Massachusetts Institute of Technology. He is the author of more than 100 publications, including 10 books, and holds more than 20 U.S. and foreign patents. Dr. Weiss performed the first retinal stem cell surgery in 2010 and is the Principal Investigator of The Stem Cell Ophthalmology Treatment Studies I/II, the largest retinal and optic nerve stem cell studies in the world, The Neurologic Stem Cell Treatment Study, The Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality Treatment Study, and The Alzheimer’s, Cognitive Impairment and Autism Treatment Study.

Buy this Course